HIV / AIDS

The Affordable Care Act can remove financial barriers and increase access to PrEP, the study authors said.

A major genetic risk factor for COVID-19, inherited from Neandertals, significantly reduces the risk of contracting HIV.

The federal agency cited chemistry manufacturing and controls issues with vials.

For people living with HIV, age-related comorbidities, such as obesity and diabetes, as well as quality-of-life issues remain challenges. Our Peer Exchange panel discusses clinical approaches for this patient population and trying to keep them in good health.

The FDA approved the One Male Condom as the first condom approved and proven to protect against STIs and HIV during anal sex.

A review of treatment modalities for this patient population.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.

Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

A study found 5% of German test-site visitors had a sexually transmitted infection. STI rates, including HIV incidence, were highest among men who have sex with men.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.

Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.

Investigators found a couple of different factors for this phenomenon.

In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

One study presented at CROI 2022 found that HIV PrEP awareness increased among Latinx/Hispanic men who have sex with men, but usage has remained relatively stable for several years.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

Urgent efforts are needed to speed the process for HIV testing among children living with HIV in sub-Saharan Africa and countries with a high HIV burden, the study authors said.

For the first time, investigators from the Wistar Institute created a DNA-based vaccine that successfully produced tier-2 antibodies capable of neutralizing HIV in mice.

Investigators modeled what a long-acting injectable HIV prevention medication would have to cost in order for it to be justified when compared to generic, oral PrEP for HIV patients and transmission prevention.

The VB variant likely originated in the late 1990s, and if left untreated, is more transmissible and deadly than prior HIV strains.

The first study to estimate rates of undiagnosed HIV in children across sub-Saharan Africa found significant gaps in HIV testing.

States that required ongoing medical doctor supervision of nurse practitioners and physician assistants had fewer HIV PrEP prescriptions.

Researchers could be one step closer to an HIV vaccine. This one uses mRNA technology.

The FDA label expansion means adults living with HIV can now receive an injection of cabotegravir and rilpivirine (Cabenuva) once every 2 months instead of once monthly.